Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

IVY-JOAN MADU

Allopathic & Osteopathic Physicians Internal Medicine Endocrinology, Diabetes & Metabolism

NPI
1710988662
CMS profile
214266
Location
ORANGE, CA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2025 · Entire year

$6,311.20

60 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2025 · entire year · sorted by reported total

Nature of paymentAmountRecords
Consulting Fee $5,080.00 2
Food and Beverage $1,188.70 57
Education $42.50 1

By paying entity

PY2025 · entire year · sorted by reported total

Page 2 of 2; records 51–60 of 60 matching records. This page contains 10 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

IVY-JOAN MADU

NPI 1710988662 · CMS profile ID 214266

Allopathic & Osteopathic Physicians / Internal Medicine / Endocrinology, Diabetes & Metabolism

ORANGE, CA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 2; records 51–60 of 60 matching records. This page contains 10 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1710988662?year=2025&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
IVY-JOAN MADU, NPI 1710988662, CMS profile ID 214266. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–60 of 60 matching records. This page contains 10 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1710988662?year=2025&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
APA 7
IndustryPayments. (2026). IVY-JOAN MADU, NPI 1710988662, CMS profile ID 214266. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–60 of 60 matching records. This page contains 10 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1710988662?year=2025&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
Bluebook
IVY-JOAN MADU, NPI 1710988662, CMS profile ID 214266, IndustryPayments, General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 2; records 51–60 of 60 matching records. This page contains 10 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e. https://industrypayments.org/provider/npi-1710988662?year=2025&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2025 · Physicians and non-physician practitioners · CMS publication 2026-06-30

60 matching records · $6,311.20 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 60 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–60 of 60.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Amgen Inc. $4.6404/01/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1227197975 CMS
Medtronic, Inc. $15.9203/28/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1219014791 CMS
Amgen Inc. $18.9003/11/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1228314425 CMS
Lilly USA, LLC $18.6103/07/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1186642179 CMS
Amgen Inc. $7.8402/25/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1227197979 CMS
Tandem Diabetes Care, Inc. $25.6802/21/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1241306991 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $18.6302/14/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1223034076 CMS
Ascendis Pharma Endocrinology Inc $24.1502/08/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1237033229 CMS
Amgen Inc. $8.0801/28/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1227197969 CMS
Amgen Inc. $18.2001/08/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1228314421 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $6,119.98 115
PY2020 $306.77 15
PY2021 $14.22 1
PY2022 $213.79 7
PY2023 $229.13 18
PY2024 $247.34 18
PY2025 $6,311.20 60

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $707,130.75 42
PY2024 Recipient $1,910.77 13
PY2024 Principal investigator $377,431.13 17
PY2023 Principal investigator $457,740.35 17
PY2022 Recipient $9,232.00 2
PY2022 Principal investigator $289,499.33 122
PY2021 Recipient $1,146.35 1
PY2021 Principal investigator $143,539.66 15
PY2020 Recipient $6,983.34 2
PY2020 Principal investigator $46,361.07 16
PY2019 Principal investigator $32,749.46 16

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

42 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 ABBVIE INC. $5,734.00 12/31/2025 Non-covered Recipient Entity
DIABETES ASSOCIATES MEDICAL GROUP
A Phase 2/3 multicenter, double blinded, randomized, dose-conversion, active control study examining the efficacy and safety of Armour Thyroid compared to synthetic T4 for the treatment of adults with primary hypothyroidism No dispute reported 06/30/2026 1202532460
Principal investigator 1 Boehringer Ingelheim International GmbH $39.96 12/17/2025 Non-covered Recipient Entity
Diabetes Associates Medical Group
A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. No dispute reported 06/30/2026 1220618658
Principal investigator 1 Boehringer Ingelheim International GmbH $255.50 12/17/2025 Non-covered Recipient Entity
Diabetes Associates Medical Group
A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. No dispute reported 06/30/2026 1220618660
Principal investigator 1 ABBVIE INC. $19,568.29 12/05/2025 Non-covered Recipient Entity
IVY-JOAN MADU
A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202529284
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $3,338.48 12/05/2025 Non-covered Recipient Entity
Diabetes Associates Medical Group
A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. No dispute reported 06/30/2026 1220993999
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 12/01/2025 Non-covered Recipient Entity
Diabetes Associates Medical Group
A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. No dispute reported 06/30/2026 1220618652
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $3,338.48 11/21/2025 Non-covered Recipient Entity
Diabetes Associates Medical Group
A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. No dispute reported 06/30/2026 1220993997
Principal investigator 1 ABBVIE INC. $81,034.24 11/05/2025 Non-covered Recipient Entity
IVY-JOAN MADU
A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202522909
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 11/01/2025 Non-covered Recipient Entity
Diabetes Associates Medical Group
A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. No dispute reported 06/30/2026 1220618650
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $3,338.48 10/28/2025 Non-covered Recipient Entity
Diabetes Associates Medical Group
A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. No dispute reported 06/30/2026 1220993993
Principal investigator 1 Boehringer Ingelheim International GmbH $639.36 10/27/2025 Non-covered Recipient Entity
Diabetes Associates Medical Group
A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. No dispute reported 06/30/2026 1220618654
Principal investigator 1 Boehringer Ingelheim International GmbH $73.00 10/27/2025 Non-covered Recipient Entity
Diabetes Associates Medical Group
A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. No dispute reported 06/30/2026 1220618656
Principal investigator 1 ABBVIE INC. $550.00 10/22/2025 Non-covered Recipient Entity
IVY-JOAN MADU
A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202518063
Principal investigator 1 ABBVIE INC. $350.00 10/21/2025 Non-covered Recipient Entity
IVY-JOAN MADU
A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202517485
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $1,669.24 10/17/2025 Non-covered Recipient Entity
Diabetes Associates Medical Group
A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. No dispute reported 06/30/2026 1220993995
Principal investigator 1 ABBVIE INC. $550.00 10/09/2025 Non-covered Recipient Entity
IVY-JOAN MADU
A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202514049
Principal investigator 1 ABBVIE INC. $49,851.06 10/09/2025 Non-covered Recipient Entity
IVY-JOAN MADU
A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202514051
Principal investigator 1 ABBVIE INC. $110.00 10/09/2025 Non-covered Recipient Entity
IVY-JOAN MADU
A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202514053
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 10/01/2025 Non-covered Recipient Entity
Diabetes Associates Medical Group
A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. No dispute reported 06/30/2026 1220618648
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $1,380.00 09/23/2025 Non-covered Recipient Entity
Diabetes Associates Medical Group Inc
A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. No dispute reported 06/30/2026 1220790898
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $12,530.40 09/23/2025 Non-covered Recipient Entity
Diabetes Associates Medical Group Inc
A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. No dispute reported 06/30/2026 1220790900
Principal investigator 1 ABBVIE INC. $53,056.36 09/04/2025 Non-covered Recipient Entity
IVY-JOAN MADU
A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202509490
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 09/01/2025 Non-covered Recipient Entity
Diabetes Associates Medical Group
A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. No dispute reported 06/30/2026 1220618646
Principal investigator 1 ABBVIE INC. $770.00 08/11/2025 Non-covered Recipient Entity
IVY-JOAN MADU
A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202504191
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $6,676.96 08/08/2025 Non-covered Recipient Entity
Diabetes Associates Medical Group
A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. No dispute reported 06/30/2026 1220993991
Principal investigator 1 ABBVIE INC. $48,026.30 08/06/2025 Non-covered Recipient Entity
IVY-JOAN MADU
A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202503043
Principal investigator 1 Boehringer Ingelheim International GmbH $24.94 08/01/2025 Non-covered Recipient Entity
Diabetes Associates Medical Group
A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. No dispute reported 06/30/2026 1220618638
Principal investigator 1 Boehringer Ingelheim International GmbH $86.00 08/01/2025 Non-covered Recipient Entity
Diabetes Associates Medical Group
A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. No dispute reported 06/30/2026 1220618640
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 08/01/2025 Non-covered Recipient Entity
Diabetes Associates Medical Group
A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. No dispute reported 06/30/2026 1220618642
Principal investigator 1 Boehringer Ingelheim International GmbH $23.75 08/01/2025 Non-covered Recipient Entity
Diabetes Associates Medical Group
A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. No dispute reported 06/30/2026 1220618644
Principal investigator 1 ABBVIE INC. $500.00 07/29/2025 Non-covered Recipient Entity
IVY-JOAN MADU
A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202500328
Principal investigator 1 ABBVIE INC. $1,500.00 07/29/2025 Non-covered Recipient Entity
IVY-JOAN MADU
A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202500330
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $391.52 07/25/2025 Non-covered Recipient Entity
Diabetes Associates Medical Group
A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. No dispute reported 06/30/2026 1220791004
Principal investigator 1 ABBVIE INC. $37,533.93 07/02/2025 Non-covered Recipient Entity
IVY-JOAN MADU
A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202495139
Principal investigator 1 ABBVIE INC. $90,253.47 06/03/2025 Non-covered Recipient Entity
IVY-JOAN MADU
A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202489711
Principal investigator 1 ABBVIE INC. $51,324.37 05/07/2025 Non-covered Recipient Entity
IVY-JOAN MADU
A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202483497
Principal investigator 1 ABBVIE INC. $40,997.25 04/03/2025 Non-covered Recipient Entity
IVY-JOAN MADU
A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202473144
Principal investigator 1 ABBVIE INC. $58,472.12 03/07/2025 Non-covered Recipient Entity
IVY-JOAN MADU
M21-341 - A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202461223
Principal investigator 1 ABBVIE INC. $29,935.64 02/06/2025 Non-covered Recipient Entity
IVY-JOAN MADU
M21-341 - A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202448302
Principal investigator 1 Eli Lilly and Company $1,299.15 01/27/2025 Non-covered Recipient Entity
IVY JOAN E MADU MD
THE EFFECT OF TIRZEPATIDE VERSUS DULAGLUTIDE ON MAJOR ADVERSE CARDIOVASCULAR EVENTS IN PATIENTS WITH TYPE 2 DIABETES (SURPASS CVOT) No dispute reported 06/30/2026 1187883754
Principal investigator 1 Eli Lilly and Company $15,099.00 01/21/2025 Non-covered Recipient Entity
IVY JOAN E MADU MD
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFECT OF TIRZEPATIDE ON THE REDUCTION OF MORBIDITY AND MORTALITY IN ADULTS WITH OBESITY No dispute reported 06/30/2026 1187885210
Principal investigator 1 Eli Lilly and Company $86,572.00 01/07/2025 Non-covered Recipient Entity
IVY JOAN E MADU MD
THE EFFECT OF TIRZEPATIDE VERSUS DULAGLUTIDE ON MAJOR ADVERSE CARDIOVASCULAR EVENTS IN PATIENTS WITH TYPE 2 DIABETES (SURPASS CVOT) No dispute reported 06/30/2026 1187885212